作者: R. Reeves , M. Thiruchelvam , D.A. Cory-Slechta
DOI: 10.1016/J.BRAINRES.2004.01.079
关键词: Antagonist 、 Sensitization 、 Dopamine receptor D1 、 Remoxipride 、 NBQX 、 SCH-23390 、 Pharmacology 、 AMPA receptor 、 Receptor antagonist 、 Chemistry 、 Developmental biology 、 General Neuroscience 、 Molecular biology 、 Clinical neurology
摘要: Triadimefon (TDF) is a triazole fungicide that blocks the reuptake of dopamine (DA), much like cocaine. A recent study in our laboratory found intermittent injections TDF led to robust locomotor sensitization response challenge after 2-week withdrawal period. The current sought determine whether expression behavioral could be prevented by DA D1-like receptor antagonist SCH 23390 (SCH), D2-like remoxipride (Rem), competitive NMDA CPP, or AMPA NBQX. Adult male C57/BL6 mice were injected with vehicle 75 mg/kg twice week for 7 weeks, activity measured periodically across 14 doses. After period, pretreated (0.015 mg/kg), Rem (0.3 CPP (2.5 mg/kg) NBQX (10.0 followed 30 min later and tested sensitization. Intermittent administration development terms vertical activity. Pretreatment SCH, successfully blocked TDF, while pretreatment did not. All four antagonists, however, attenuated neurochemical changes normally associated as 8 h challenge. This paper reveals NMDA, receptors are necessary triadimefon.